Taken together, these studies suggest that defining endometrial cancers by both molecular characteristics and clinicopathologic features is a more effective way to assess risk factor and treatment options, particularly in the case of CTNNB1 mutations. This evidence concerns the gene CTNNB1 and endometrial cancer.